References
- Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37 (3 ), 377 – 388 (2012).
- Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 95 (15 ), 8869 – 8873 (1998).
- Blankson JN, Finzi D, Pierson TC et al. Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection. J. Infect. Dis. 182 (6 ), 1636 – 1642 (2000).
- Ananworanich J, Sacdalan CP, Pinyakorn S et al. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J. Virus Erad. 2, 43 – 48 (2016).
- Hatano H, Bacon O, Cohen S et al. Lack of detectable HIV DNA in a PrEP study participant treated during hyperacute HIV infection. Presented at : The Conference of Retroviruses and Opportunistic Infections. MA, USA, 3–6 March 2014.
- Persaud D, Gay H, Ziemniak C et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369 (19 ), 1828 – 1835 (2013).
- Henrich TJ, Hanhauser E, Marty FM et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161 (5 ), 319 – 327 (2014).
- Hütter G, Nowak D, Mossner M et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360 (7 ), 692 – 698 (2009).
- Laird GM, Bullen CK, Rosenbloom DI et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J. Clin. Invest. 125 (5 ), 1901 – 1912 (2015).
- Spivak AM, Planelles V. HIV-1 eradication: early trials (and tribulations). Trends Mol. Med. 22 (1 ), 10 – 27 (2016).
- Chun TW, Carruth L, Finzi D et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387 (6629 ), 183 – 188 (1997).
- Ho YC, Shan L, Hosmane NN et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155 (3 ), 540 – 551 (2013).
- Shan L, Deng K, Shroff NS et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36 (3 ), 491 – 501 (2012).
- Blankson JN, Bailey JR, Thayil S et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J. Virol. 81 (5 ), 2508 – 2518 (2007).
- Migueles SA, Connors M. Success and failure of the cellular immune response against HIV-1. Nat. Immunol. 16 (6 ), 563 – 570 (2015).
- Hansen SG, Piatak M Jr, Ventura AB et al. Immune clearance of highly pathogenic SIV infection. Nature 502 (7469 ), 100 – 104 (2013).
- Sung JA, Lam S, Garrido C et al. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J. Infect. Dis. 212 (2 ), 258 – 263 (2015).
- Walker-Sperling VE, Cohen VJ, Tarwater PM, Blankson JN. Reactivation kinetics of HIV-1 and susceptibility of reactivated latently infected CD4+ T cells to HIV-1-specific CD8+ T cells. J. Virol. 89 (18 ), 9631 – 9638 (2015).
- Jones RB, O'Connor R, Mueller S et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog. 10 (8 ), e1004287 (2014).
- Walker-Sperling VE, Pohlmeyer CW, Tarwater PM, Blankson JN. The effect of latency reversal agents on primary CD8+ T cells: implications for shock and kill strategies for Human Immunodeficiency Virus eradication. Presented at : The Conference of Retroviruses and Opportunistic Infections. MA, USA, 22–25 February 2016.
- Denton PW, Long JM, Wietgrefe SW et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 10 (1 ), e1003872 (2014).
- Sung JA, Pickeral J, Liu L et al. Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J. Clin. Invest. 125 (11 ), 4077 – 4090 (2015).